MD, PhD, MBA
Dr. David Greene, MD, PhD, MBA, stands at the forefront of regenerative medicine and healthcare innovation, blending clinical expertise with entrepreneurial vision. As the founder and CEO of R3 Stem Cell and US Lead Network, Dr. Greene has dedicated his career to advancing patient care and empowering medical practices through advanced therapies and digital marketing excellence.
A residency and fellowship-trained orthopedic surgeon, Dr. Greene began his journey in medicine with a deep commitment to helping others. After years in clinical practice, he recognized the transformative potential of regenerative therapies and the urgent need for better patient access and education. This insight led him to establish R3 Stem Cell, now a global leader in non-surgical treatment options using stem cell and PRP therapy. Under his leadership, R3 Stem Cell has performed over 26,000 procedures across more than 45 international clinics, offering hope and healing to patients worldwide.
Dr. Greene’s entrepreneurial spirit didn’t stop at clinical innovation. He also founded US Lead Network, a healthcare internet marketing company that leverages artificial intelligence to help medical and dental practices grow their patient base efficiently and ethically. His two books on healthcare internet marketing have become essential reading for providers seeking to navigate the complexities of digital patient acquisition. Recognized as a Top 20 Expert Author by Ezines.com – ranking #15 out of over 470,000 authors and #1 in Pain Management – Dr. Greene’s thought leadership has shaped the way healthcare professionals connect with patients online.
A defining moment in Dr. Greene’s career was his decision to leave clinical practice and focus entirely on innovation and education. “I’ve never been a fan of just settling for the status quo. Innovation is a cornerstone of what makes America great,” he reflects. This philosophy has driven R3 Stem Cell’s mission to provide affordable, high-quality regenerative care and to demystify stem cell therapies through comprehensive training courses and educational content for both providers and patients.
Dr. Greene’s work has garnered international recognition, including a feature on the cover of Corporate Vision magazine, where his commitment to affordable, accessible regenerative therapies was spotlighted. His impact extends beyond business metrics – he is known for his compassionate approach, always prioritizing patient education and ethical practice.
Outside of his professional life, Dr. Greene is inspired by the words of Maya Angelou: “My mission in life is not merely to survive, but to thrive; and to do so with some passion, some compassion, some humor, and some style”. He brings this ethos to his daily work, fostering a culture of innovation, empathy, and continuous learning.
When he’s not leading global healthcare initiatives, Dr. Greene enjoys sharing insights on social media, connecting with colleagues, and pursuing personal interests that keep him grounded and inspired.
Dr. David Greene’s journey is a testament to the power of combining clinical skill, business acumen, and a heartfelt commitment to making a difference – one patient, one practice, and one innovation at a time.
All Posts
If you’re researching regenerative medicine for a joint condition — osteoarthritis, a rotator cuff tear, or other soft tissue injuries — you’ve likely encountered two therapies: mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP). Many regenerative clinics now use both together rather than either alone.
Diabetes affects more than 537 million adults worldwide and remains the eighth leading cause of death globally. Projections suggest that the number will climb roughly 46% over the next two decades — making durable, effective treatments one of medicine’s most pressing priorities. Conventional management with
Multiple sclerosis is a chronic autoimmune disease in which the immune system attacks the myelin sheath protecting nerve fibers in the brain and spinal cord. Symptoms range from walking difficulty and fatigue to cognitive changes and progressive disability. Most approved therapies slow MS but do
When Beverly Bincey’s husband Richard began declining despite years of conventional treatment for Parkinson’s disease, she started looking beyond standard options. That search brought the couple from North Carolina to Knoxville, Tennessee, where Richard received an IV stem cell infusion at R3 Stem Cell under
From the Field to the Treatment Table If you’re managing joint pain, arthritis, or a soft tissue injury, chances are you’ve already had a steroid injection — or been offered one. They’re fast, familiar, and widely covered by insurance. But as regenerative medicine advances, more
From the Field to the Treatment Table Fourteen grueling seasons in the NFL inevitably leave a mark. For veteran tight end Delanie Walker, the physical toll manifested as chronic knee inflammation and a damaged shoulder that required far more than standard rest and ice. Instead
For millions of people living with knee osteoarthritis, finding durable, effective pain relief without surgery is a constant challenge. Hyaluronic acid (HA) injections—sometimes called “rooster comb” injections or viscosupplementation—have been a go-to non-surgical option for decades. But for many patients, their effectiveness diminishes over time.
For athletes, an injury is never just physical — it threatens identity, career, and competitive future. When a compound knee injury sidelined a young high-level athlete, her father, a former professional athlete himself, didn’t hesitate. Based on firsthand knowledge of R3 Stem Cell through his
For many living with chronic pain, the morning ritual isn’t about coffee or a commute — it’s about managing the heavy feeling of inflammation and the sharp stiffness of arthritis. When traditional interventions like surgery or long-term medication use reach their limits, patients are increasingly
Peripheral neuropathy is a staggering global health issue, stemming from over 100 distinct causes. It is most prevalent among diabetics—affecting nearly 50% of that population—and cancer survivors, with upwards of 85% of chemotherapy patients experiencing some form of nerve damage. Other contributors include heavy metal
